Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor.

ABSTRACT: We conducted this three-part study in healthy subjects to investigate the pharmacokinetics of tasurgratinib (orally available selective inhibitor of fibroblast growth factor receptor 1-3) and M2 (its major metabolite) under different conditions. In Part A, subjects received tasurgratinib 35 mg either fed with a high-fat meal or fasted. In Parts B and C, subjects received tasurgratinib 35 mg alone or with either rabeprazole (acid-reducing agent) 20 mg (Part B) or rifampin (strong CYP3A inducer) 600 mg (Part C). Primary endpoints were maximum concentration (C_max), and areas under the plasma concentration-time curve to time of last quantifiable concentration (AUC_(0-t)) and extrapolated to infinite time (AUC_(0-inf)). Forty-two subjects were enrolled, 14 each in

SUBMITTER: Nomoto M 

PROVIDER: S-EPMC11591400 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature